AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application (sBLA) seeking approval for expanded use of Enhertu (trastuzumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback